The latest health & wellness articles from TheMurrow. In-depth analysis and reporting on the topics that matter.
As FDA enforcement tightens, “copycat” access doesn’t disappear—it morphs into euphemisms, additives, and quieter sourcing changes. The danger isn’t only counterfeits; it’s ambiguity you can’t audit once it’s in the vial.
Some watches don’t truly “measure” blood pressure—they estimate it, anchored to cuff readings you must refresh every 28 days. That monthly reset can change your baseline, your trust, and how you interpret your health even when nothing is wrong.
Samsung finally flipped on blood-pressure monitoring for Galaxy Watch owners in the U.S.—but the reading is only as trustworthy as your monthly cuff calibration. The “boring step” is the entire point: it reveals this is a cuff-dependent estimate, not a clinic-grade replacement.
The FDA’s “resolved” label is national policy—not a guarantee at your pharmacy counter. Price, insurance gatekeeping, and telehealth convenience keep compounded vials in motion, even as enforcement tightens.
The Nancy case isn’t a referendum on the cap you twist off at lunch—it’s about alleged contamination at the source, tied to historic bottle dumps. Meanwhile, the plastic many consumers fear often enters later, during bottling and packaging.
The FDA’s rare, high-volume warning-letter burst targets a specific internet-era problem: marketing that makes compounded GLP‑1s feel indistinguishable from Ozempic, Wegovy, Mounjaro, or Zepbound—right at the moment patients decide to inject.
A 2026 peer‑reviewed study sent three identical NIST stool samples to seven direct‑to‑consumer microbiome testing services—and got meaningfully different results. If the input is the same but the “truth” changes, the instability isn’t your gut—it’s the measurement.
The FDA just fired 30 warning letters at telehealth brands selling compounded GLP‑1s with “same as” vibes and brand-forward sourcing blur. With shortages over, the loophole-era language is becoming the liability—and patients will feel the whiplash first.
The FDA ended the national shortage listing for Ozempic and Wegovy—but the vial-and-syringe semaglutide market didn’t disappear. It adapted, and regulators are signaling they’re done indulging the workaround.
OTC CGMs made glucose a consumer metric—but the line you’re watching is delayed, averaged, and easy to moralize. The biggest “spikes” are where interpretation is least reliable.
Creatine has gone from shaker-bottle staple to candy-like wellness accessory—especially for women. But the category’s simplest mantra (“just take 5 grams”) collides with gummy serving sizes, uneven women-specific evidence, and real-world adherence.
Cuffless “BP” can be an estimate or a risk signal—often built on optical pulse data, not arterial pressure. The AHA says: show validation, disclose calibration, prove it in real life.
A science-backed micro-routine you can repeat anywhere—at home, at your desk, or between meetings—to lower stress and restore steadier energy.
A science-backed micro-routine to help you downshift fast, sleep better over time, and create a repeatable boundary between day and night.
A science-backed micro-routine to stop carrying the day into the night—lower arousal, steady attention, and make sleep easier to approach in just ten minutes.
A science-backed micro-routine built from light, movement, and breathing—small enough for bad days, powerful enough to shift energy, mood, and sleep over time.
A science-backed micro-routine to downshift stress, improve sleep onset, and reclaim steadier energy—without pretending ten minutes can fix everything.
A science-backed routine for better sleep, steadier energy, and more stress resilience—built to survive real life in just 10 minutes a day.
A small, repeatable ritual can nudge stress, alertness, and sleep in the right direction. Not magic—mechanism, built for modern schedules.
A science-backed micro-routine to downshift stress, quiet rumination, and strengthen bedtime cues—so sleep, energy, and mood have a better chance.